Specific features of medicines safety and pharmacovigilance in Africa

Therapeutic Advances in Drug Safety

Volumn 3, Issue 1, 2012, Pages 25-34

  Isah, Ambrose O ^a   Pal, Shanthi N ^b   Olsson, Sten ^c   Dodoo, Alexander ^d   Bencheikh, Rachida Soulayami ^e  

^a UNIVERSITY OF BENIN   (Nigeria)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c UPPSALA MONITORING CENTRE   (Sweden)

^d UNIVERSITY OF GHANA   (Ghana)

^e Moroccan Pharmacovigilance Centre   (Morocco)

Author keywords

adverse drug reactions; Africa; medicines safety; pharmacovigilance

Indexed keywords

COUNTERFEIT DRUG;

AFRICA; ANGIONEUROTIC EDEMA; DRUG LEGISLATION; DRUG MARKETING; DRUG QUALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ETHNIC DIFFERENCE; EUROPE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HIGH RISK POPULATION; HUMAN; INCOME; MASS MEDIUM; MEDICATION ERROR; NEGRO; PHARMACOGENOMICS; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RACE DIFFERENCE; REVIEW; SELF MEDICATION; SYSTEMATIC REVIEW (TOPIC); TRADITIONAL MEDICINE; TREATMENT RESPONSE; UNITED STATES;

EID: 84859088989     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098611425695     Document Type: Review

References (28)

1. Ali L. Benkirane R. Soulaymani R. (2007) Detecting medication errors in pharmacovigilance database: capacities and limits. Int J Risk Saf Med 19: 1–18.
2. Bencheikh R.S. (2009) Medication errors: pharmacovigilance centres in detection and prevention. Br J Clin Pharmacol 67: 687–690.
3. Dodoo A. Adjei S. Couper M. Hugman B. Edwards R. (2007) When rumours derail a mass deworming exercise. Lancet 370: 465–466.
4. Eliasson E. (2006) Ethnicity and adverse drug reactions. BMJ 332: 1163.
5. Hetherington S. Hughes A.R. Mosteller M. Shortino D. Baker K.L. Spreen W. (2002) Genetic variations in HLA-B region and hypersensitivity to abacavir. Lancet 359: 1121–1122.
6. Hussain K. Majeed M.T. Ismail Z. Sadikun A. Ibrahim P. (2009) Traditional and complementary medicines: quality assessment strategies and safe usage. Southern Med Review 2: 19–23.
7. Isah A.O. Isah E.C. (1998) Drug information sources utilised by junior hospital doctors in the absence of a formal service in a developing country setting. Nat Postgrad Med J 5: 23–27.
8. Jasso-Gutiérrez L. Castellanos-Solis E.C. Santos-Preciado J.I. (2009) The importance of pharmacovigilance in the pediatric population. Bol Med Hosp Infant Mex 66: 3–15.
9. Kinfu Y. Dal Poz M.R. Mercer H. Evans D.B. (2009) The health worker shortage in Africa: are enough physicians and nurses being trained?. Bull World Health Organ 87: 225–230.
10. Kremer M. (2002) Pharmaceuticals and the developing world. J Econ Perspect 16: 67–90.
11. Kudzi W. Dodoo A.N. Mills J.J. (2009) Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC Med Genet 10: 124.
12. McBride W.G. (1961) Thalidomide and congenital abnormalities. Lancet 278: 1358.
13. McDowell S.E. Coleman J.J. Ferner R.E. (2006) Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 332: 1177–1180.
14. Ojewole J.A. Olusi S.O. (1976) Effects of cow–s urine concoction on plasma glucose concentration in fasted rats. Trans R Soc Trop Med Hyg 71: 241–245.
15. Olsson S. Shanthi P. Stergachis A. Couper M. (2010) Pharmacovigilance activities in 55 low – and middle- income countries. A questionnaire-based analysis. Drug Saf 33: 689–703.
16. Parikh S. Ouedraogo J.B. Goldstein J.A. Rosenthal P.J. Kroetz D.L. (2007) Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther 82: 197–203.
17. Pirmohamed M. Atuah K.N. Dodoo A.N.O. Winstanley P. (2007) Pharmacovigilance in developing countries. BMJ 335: 462.
18. Rovira J. (2002) Pharmaceuticals, globalization and developing countries: recent developments and challenges. Pharmaceut Policy Law 5: 7–10.
19. Stergachis A. Bartlein R.J.K. Dodoo A. Nwokike J. Kachur P.S. (2010) A situational analysis of pharmacovigilance plans in the Global Fund Malaria and U.S. President–s Malaria Initiative proposals. Malaria J 9: 148.
20. United Nations (2007) Human Development Report – Per Capita Health Expenditures by Country. www.hdr.undp.org (accessed 18 September 2011).
21. Venulet J. Helling-Borda M. (2010) WHO–s international drug monitoring – the formative years, 1968–1975. Preparatory, pilot and early operational phases. Drug Saf 33: e1–e23.
22. World Health Organization. (2002) The Importance of Pharmacovigilance Safety Monitoring of Medicinal Products, Geneva, p. 7.
23. World Health Organization. (2006) Using indicators to measure country pharmaceutical situations. Fact Book on WHO level I and level II monitoring indicators, Geneva.
24. World Health Organization. (2008a) The Global Burden of Disease, Geneva.
25. World Health Organization. (2008b) Practical Handbook on Pharmacovigilance of Antimalarial Medicines, Geneva.
26. World Health Organization. (2009) Pharmacovigilance sans Frontiers (PVSF) Meeting Reports on Counterfeit and Substandard Medicines, Maputo, Mozambique.
27. World Health Organization. (2010) Pharmacovigilance sans Frontiers (PVSF) Meeting Reports on Counterfeit and Substandard Medicines, Lome, Togo.
28. Yadav S. (2008) Status of adverse drug reaction monitoring and pharmacovigilance in selected countries (2008). Indian J Pharmacol 40(Suppl. 1: S4–S9.